Nick Glover
Board of Directors @Lite Strategy
Signup · Get unlimited contacts
WORK HISTORY
Board of Directors @Lite Strategy
Chair, Compensation CommitteeMember, Audit CommitteeMEI Pharma, Inc.(Nasdaq: MEIP) is a pharmaceutical company developing novel and differentiated therapies. Our drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (\"CDK9\") inhibitor. In July 2025, MEIP launched a treasury strategy focused on Litecoin, becoming the first and only publicly traded LTC holder on a national exchange.
EDUCATION
Simon Fraser University
Ph.D., Chemistry
The University of British Columbia
M.Sc., Chemistry
University of East Anglia
B.Sc. (Hons), Chemistry
ABOUT NICK GLOVER
Chief Executive Officer (20+ years; 3x public) with extensive strategic, financial and operational experience in the biotechnology sector, evidenced by demonstrable value creation and successful outcomes. Hands-on track record in drug discovery & pharmaceutical development (25+ years), including Ojjaara (momelotinib) for myelofibrosis. Deep expertise in oncology, from whiteboard discovery to translation through multiple registration-intent studies. Led the strategic & clinical/operational development of assets representing >$4.5B in realized & peak value. Raised >$700M in public equity capital; involved in >$1.35B in aggregate financings. Experienced public & private Board Director. Strategic adviser to drug discovery & development companies.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.